Japanese Influencer and Cabaret Hostess Apologizes for Promoting Diabetes Drug as Weight-Loss Aid, Suspends Activities

 A popular Japanese influencer and cabaret hostess known as Yui Pis (ゆいぴす) has issued a public apology after facing widespread criticism for comments promoting the diabetes medication Mounjaro (tirzepatide, marketed as Manjaro in Japan) for non-medical weight loss. In a recent YouTube appearance and social media posts, she acknowledged the issue and announced a pause in her influencer work.

The controversy centers on pharmaceutical advertising regulations in Japan. Mounjaro is approved for treating type 2 diabetes, but its appetite-suppressing effects have led to off-label use for dieting. Japanese law (the Pharmaceutical Affairs Law, or Yakki-hō) strictly limits promotion of prescription drugs by non-medical professionals to protect public health.

The Apology and Its ContextOn June 3, 2026, Yui Pis updated her X (formerly Twitter) account and referenced a YouTube video where she addressed the matter directly. She stated:

“Regarding the recent issue with Manjaro, I am truly sorry. To those who felt uncomfortable or anxious, and to my supporters, I offer my heartfelt apologies. I recognize that my statements may have violated pharmaceutical regulations. As someone with influence, I should have prioritized the health and safety of my followers.”

She further advised anyone who purchased the drug based on her comments to consult a doctor or pharmacist about potential risks. In addition, she stepped down as an ambassador for related promotions, withdrew from an upcoming large-scale event (LAST CALL COLLECTION), and distanced herself from associated business activities.The situation gained traction after clips from her YouTube show LAST CALL circulated, where she reportedly suggested the drug casually in a conversation about weight management. Earlier posts showed her defending her involvement by questioning whether non-doctors could discuss medications and highlighting the drug’s global popularity.English-Language Coverage and International InterestEnglish discussions have primarily appeared on Reddit (r/japan and r/japannews) and social media platforms. A Reddit thread titled “Japanese Influencer ゆいぴす Faces Backlash for Promoting Diabetes Drug Mounjaro for Weight Loss” summarized the events, noting her background as a 24-year-old Roppongi cabaret hostess and her prior viral video of self-administering the injection.International observers have drawn parallels to broader global debates around GLP-1 drugs like Ozempic and Mounjaro, which have surged in popularity for cosmetic weight loss despite being intended for chronic conditions. Some commentary highlighted concerns about influencers promoting prescription medications to younger or non-obese audiences.Mainstream English news outlets have not yet published extensive reporting as the story is developing rapidly in Japanese media.Japanese Public ReactionsReactions on Japanese platforms, particularly X, have been mixed but largely critical of the initial promotion:

• Many users expressed relief at the apology, describing it as sincere and mature. Some noted it appeared thoughtful and urged others to stop excessive criticism.
• Others questioned the timing and suggested the apology and withdrawals (including from events and partnerships) may relate to ongoing regulatory scrutiny or police actions involving similar promotions.
• Discussions often emphasize responsibility: while some sympathize with the pressures on young influencers, others stress that public figures should avoid recommending prescription drugs without medical qualifications.
• Supporters have highlighted her transparency in addressing follower concerns directly.

The episode has sparked wider conversations in Japan about influencer marketing, online pharmacies, and the responsible use of weight-loss medications. Authorities continue to monitor off-label promotion cases to safeguard consumers.This story is ongoing, with potential further developments from regulatory bodies. Health experts generally recommend consulting licensed physicians before using any prescription medication.